Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Effect of Candesartan and Various Inflammatory Markers on Maintenance of Sinus Rhythm After Electrical Cardioversion for Atrial Fibrillation
2007
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
2005
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
2010 Standout
Perioperative Management of Antithrombotic Therapy
2012 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition
2010
Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
2006
Is atrial fibrillation an inflammatory disorder?
2005
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
2006
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension
2006
Status of the Epidemiology of Atrial Fibrillation
2007
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
2006
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention
2011
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
2009 Standout
Conflicts of Interest in Cardiovascular Clinical Practice Guidelines
2011 Standout
Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?
2005
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
Structural and Functional Remodeling of the Left Atrium
2008
Biomarkers in Heart Failure
2008 Standout
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
2006
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
2009 Standout
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
2010 Standout
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Atrial Fibrillation and Heart Failure
2009
A New Automatic Identification Method of Heart Failure Using Improved Support Vector Machine Based on Duality Optimization Technique
2019
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
2006
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2006
Heart Disease Identification Method Using Machine Learning Classification in E-Healthcare
2020 Standout
2007 ESH‐ESC Guidelines for the management of arterial hypertension
2007
Works of E Cerè being referenced
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
2005